Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NIS793 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
MOH_2021-12-06_010444Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nisevokitug in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Novartis. Primary endpoints: Overall survival and Recommended phase 3 dose confirmation. Started Dec 2021; status: active, not recruiting.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2021-12-06_010444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-06_010444.